Welcome to our dedicated page for CytoMed Therapeutics Ordinary Shares news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics Ordinary Shares stock.
CytoMed Therapeutics Limited, established in 2018, is a Singapore-based biopharmaceutical company spun off from the Agency for Science, Technology and Research (A*STAR). The company leverages its proprietary technologies to develop groundbreaking cell-based immunotherapies for the treatment of various cancers. CytoMed Therapeutics focuses on utilizing patented gamma delta (γδ) T cell and natural killer (NK) cell-based therapies, creating 'off-the-shelf' solutions aimed at a wide range of cancers. Their innovative approach also includes generating induced pluripotent stem cells (iPSCs) to develop cellular therapeutics tailored to customer needs.
The company’s cutting-edge developments are inspired by the success of CAR-T cells in treating hematological malignancies and addressing the limitations and challenges of applying CAR-T principles to solid tumors. CytoMed operates primarily in Singapore and Malaysia, with the latter being a significant revenue contributor.
Recently, CytoMed Therapeutics announced significant advancements, including the granting of a patent by the China National Intellectual Property Administration (CNIPA) for its iPSC-based technology. This development expands the company's patent portfolio, which now includes patents in the US, China, and Japan for their allogeneic chimeric antigen receptor γδ T cells (CAR-γδ T cells) technology, poised to enter phase I clinical trials in Singapore soon.
The company’s immunotherapeutic innovations include the development of synthetic hybrid immune cells, specifically γδ NKT cells, which exhibit receptors from both γδ T cells and NK cells. These cells can recognize a broad spectrum of cancers without genetic modification, offering a potent 'off-the-shelf' therapy option for numerous patients.
CytoMed’s financial health remains robust. For the first half of 2023, the company reported a net loss of S$1.16M ($860,695), excluding IPO-related expenses. As of June 30, 2023, CytoMed had cash and cash equivalents amounting to S$10.44M ($7.72M). The company also raised S$12.94M ($9.57M) from its NASDAQ IPO in April 2023.
Furthermore, CytoMed has entered into strategic collaborations to advance its clinical objectives. Notably, it has partnered with Sengkang General Hospital in Singapore for a proof-of-concept trial using umbilical cord-derived mesenchymal stem cells (UC-MSCs) for cartilage regeneration, addressing osteoarthritis of the knee.
CytoMed Therapeutics continues to make strides in the field of cell-based immunotherapies, with their innovative efforts promising substantial advancements in cancer treatment and regenerative medicine.
CytoMed Therapeutics (NASDAQ: GDTC) has announced the dosing of its first patient in the ANGELICA Trial, a Phase I clinical trial evaluating allogeneic NKG2DL-targeting CAR gamma delta T cells (CTM-N2D) for advanced solid tumors and hematological malignancies. This marks the company's transition to a clinical-stage biopharma. Unlike traditional CAR-T therapy that uses patient's own cells, CytoMed's approach uses donor blood-derived gamma delta T cells, which can be used without donor-patient matching. This method aims to improve cell quality, reduce production costs, and increase therapy accessibility.
CytoMed Therapeutics (NASDAQ: GDTC) has received full approval for its first-in-human Phase I ANGELICA clinical trial using patented allogeneic CAR-T cell therapy against blood and solid tumors. The trial, conducted in collaboration with the National University Hospital of Singapore, is co-funded by the NMRC Clinical Trial Grant. Unlike traditional CAR-T therapies, CytoMed's approach uses gamma delta T cells from healthy donors, potentially improving quality, lowering costs, and increasing accessibility.
Additionally, CytoMed has completed a cash acquisition of a licensed cord blood bank in Malaysia, expanding its strategy into cord blood-derived biologics through its subsidiary, LongevityBank Pte This acquisition provides access to cord blood donated for research and development, supporting CytoMed's focus on cell therapies for aging diseases and regenerative medicine.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking licence and assets through its subsidiary, IPSC Depository Sdn Bhd. The acquisition includes a licence from Malaysia's Ministry of Health, cryopreservation equipment with over 12,000 cord blood units, and two freehold properties. This move expands CytoMed's strategy in cell therapies, providing access to rare cord blood for research and development in regenerative medicine and aging diseases.
The new biotechnology arm will be operated through CytoMed's subsidiary, LongevityBank Pte . Evelyn Tan, CEO of IPSC Depository Sdn Bhd, stated that this acquisition aims to unlock the therapeutic potential of umbilical cord blood, targeting longevity and wellness. CytoMed's co-CEO, Dr Tan Wee Kiat, highlighted the synergy between CytoMed and IPSC Depository in deriving immune gamma delta T cells from cord blood to fight cancers.
CytoMed Therapeutics (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has reported its financial results for the six months ended June 30, 2024, and provided clinical updates. The company is focused on developing novel donor-derived, cell-based allogeneic immunotherapies for cancer treatment.
Key highlights include:
- Ongoing recruitment for the ANGELICA Trial, a first-in-human Phase I clinical trial for allogeneic CAR-γδ T cells (CTM-N2D)
- Net loss of S$1.09 million (US$803,235) for the period
- Cash and bank balances of S$6.47 million (US$4.78 million) as of June 30, 2024
- Research and development expenses increased to S$974,402 (US$719,010)
- General and administrative expenses decreased to S$902,910 (US$666,256)
The company is progressing with its proprietary technologies and has scheduled a conference call for October 8, 2024, to discuss the results further.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking license and assets from Cellsafe International for approximately US$490,000. The acquisition includes cryopreservation equipment with over 12,000 cord blood units and two freehold properties. This move strengthens CytoMed's position in allogeneic gamma delta (γδ) T cell technology for cancer treatment.
Additionally, CytoMed has been granted a new patent in Malaysia for its iPSC-derived hybrid γδ NKT cells technology, expanding its tumor-targeting therapy patent portfolio. The company aims to develop cytotoxic γδ T cells from three sources: adult peripheral blood mononuclear cells, induced Pluripotent Stem Cells, and cord blood.
CytoMed plans to repurpose cord blood units for a wider range of therapies, including solid cancer treatment. The company is currently conducting the ANGELICA Trial, a phase 1 clinical trial in Singapore focused on CAR-T therapy.
FAQ
What is the current stock price of CytoMed Therapeutics Ordinary Shares (GDTC)?
What is the market cap of CytoMed Therapeutics Ordinary Shares (GDTC)?
What is CytoMed Therapeutics Limited?
When was CytoMed Therapeutics founded?
What are the core technologies used by CytoMed Therapeutics?
What recent patents has CytoMed earned?
What are γδ NKT cells?
Where does CytoMed Therapeutics operate?
What are the recent financial highlights for CytoMed Therapeutics?
What collaborations has CytoMed recently entered into?
What is the focus of CytoMed's research and development?
How does CytoMed use iPSCs in cancer treatment?
